Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standardized bermuda grass pollen is an allergenic extract prepared from the pollen of Cynodon dactylon, used for **diagnosis and immunotherapy of allergic diseases** caused by bermuda grass pollen. Its mechanism of action involves exposure to controlled doses of the allergen by skin test or by subcutaneous injection, leading to an immune response that helps reduce allergic symptoms and induce tolerance to bermuda grass pollen. Primary indications are allergy testing and allergen-specific immunotherapy in patients with confirmed sensitivity to bermuda grass pollen. Standardized extracts are measured in bioequivalent allergy units (BAU/ml) and are not interchangeable with non-standardized or differently-labeled extracts[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standardized bermuda grass pollen.